Thus, based on our results, clinical monitoring of post-therapeutic PD-L1 profile of CTCs should be taken into account besides PD-L1 expression scores on cancer tissues as potential basis for second line treatment decision to assist monitoring of early relapse and improve prospects of PD-L1-PD-1 immunotherapy. Here, CD274 is linked to cancer.